Review of glucagon-like peptide-1 receptor agonist use in people with HIV.
Contagion Live clinical review
People living with HIV (PLWH) face a myriad of risks for comorbidities, including metabolic complications, that extend goal therapeutic outcomes well beyond just maintaining viral suppression. The intersection of HIV infection, antiretroviral therapy, and metabolic disease has created unique clinical challenges that demand preemptive innovative therapeutic approaches. Among emerging treatment options, glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists have garnered increasing attention for their potential to address multiple metabolic complications. Although GLP-1 agonists, such as semaglutide, liraglutide, and tirzepatide (a dual GLP-1/GIP agonist), are FDA approved for several metabolic-related indications beyond adjunct diabetes mellitus treatment, such as reducing the risk of major adverse cardiovascular events and reducing further renal dysfunction for type 2 diabetes and obesity in the general population, their use in PLWH remains a promising yet evolving area of study.
Read the full review here.
Source : Contagion Live
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.